![]() |
CiteULike | ![]() |
eisei's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs |
Reviews
[Write a review of this article]
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
AbstractCD8 can serve as a co-receptor or accessory molecule on the surface of CTL. As a co-receptor, CD8 can bind to the alpha3 domain of the same MHC class I molecules as the TCR to facilitate TCR signaling. To evaluate the role of the MHC class I molecule alpha3 domain in the activation of CD8+ CTL, we have produced a soluble 227 mutant of H-2Dd, with a point mutation in the alpha3 domain (Glu227[->]Lys). 227 mutant class I-peptide complexes were not able to effectively activate H-2Dd-restricted CD8 T cells in vitro, as measured by IFN-gamma production by an epitope-specific CD8+ CTL line. However, the 227 mutant class I-peptide complexes in the presence of another MHC class I molecule (H-2Kb) (that cannot present the peptide) with a normal alpha3 domain can induce the activation of CD8+ CTL. Therefore, in order to activate CD8+ CTL, the alpha3 domain of MHC class I does not have to be located on the same molecule with the alpha1 and alpha2 domains of MHC class I. A low-avidity CD8+ CTL line was significantly less sensitive to stimulation by the 227 mutant class I-peptide complexes in the presence of the H-2Kb molecule. Thus, low-avidity CTL may not be able to take advantage of the interaction between CD8 and the alpha3 domain of non-presenting class I MHC molecules, perhaps because of a shorter dwell time for the TCR-MHC interaction. 10.1093/intimm/dxm111
BibTeX record
RIS record